Photo Credit: Chris Frawley

In a wide-ranging #SU2CInnovationSummit, scientists from many different fields discussed methods, technologies, and systems for catching cancers at their earliest stages and selecting the best treatments for every patient. #StandUpToCancer

Photo Credit: Chris Frawley

Another #SU2CInnovationSummit was focused on developing novel approaches for detecting and treating brain cancers called gliomas. #StandUpToCancer

Photo Credit: Chris Frawley

In a #SU2CInnovationSummit held today, researchers reviewed the latest data on the surge in early-onset cancers and discussed potential approaches for improving early detection and treatment of cancer in these younger patients. #StandUpToCancer

Researchers at the #SU2CScientificSummit gave us their one-word descriptions of #StandUpToCancer. Each word and phrase is a testament to our mission: Raise awareness and fund research to detect and treat cancers with the aspiration to cure all patients. 💛

We'd like to thank all the #StandUpToCancer researchers, advisors, reviewers, advocates, and funding collaborators who joined us for another motivational and powerful SU2C Scientific Summit. Together, the path to new cures is becoming clearer than ever. 🧡

The annual #SU2CScientificSummit brings together top scientists to drive bold discoveries and transformative change in cancer research.

Exciting times at the 2026 #SU2CScientificSummit @su2c.bsky.social! Delighted to share that I’ve joined my friend Dr. Peter Jones as co-leader of the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team, which moves promising potential combination therapies for cancer into clinical trials.

Photo Credit: Chris Frawley

Thank you to our wonderful keynote speakers, #StandUpToCancer Prostate Cancer Dream Team leader Dr. Arul Chinnaiyan and SU2C Science Advisory Committee Vice Chair Dr. John Carpten. #SU2CScientificSummit

Photo Credit: Chris Frawley

A full day has begun at the #SU2CScientificSummit! We received inspiring remarks from #StandUpToCancer President and CEO Dr. Julian Adams, SU2C Science Advisory Committee Chair Dr. William G. Nelson, @theaacr.bsky.social CEO Dr. Marge Foti, and SU2C co-founder Sherry Lansing.

Photo Credit: Chris Frawley

The other #SU2CInnovationSummit held today was a collaboration with the Farrah Fawcett Foundation, gathering researchers, advocates, & other stakeholders to chart a path forward for the early detection, screening, and treatment of HPV-related anal and oropharyngeal cancers. #StandUpToCancer

Photo Credit: Chris Frawley

In one #SU2CInnovationSummit held today, leading researchers discussed advances in cancer theranostics. Theranostics are like multitalented homing beacons: Molecules that allow doctors to clearly see tumors with imaging, like a PET scan, and that can also precisely deliver radiation to those tumors.

The #SU2CScientificSummit and five #SU2CInnovationSummits are taking place this week in Pasadena, California! Hundreds of scientists will be discussing the latest in cancer research and treatment, and identifying opportunities for rapid progress. Let the innovation begin! #StandUpToCancer

Gastric cancer claims more than 750,000 lives each year. In partnership with @cancerresearchuk.org, we’ve extended funding for a research dream team that has developed a way to find and stop #gastriccancer at its earliest stages, when treatment is most effective. standuptocancer.org/latest-news/...

Lung cancer screening can save lives. Black men have the highest death rates from #lungcancer. A community-engaged strategy for overcoming screening barriers developed with @SU2C funding may help change that. @medunivsc.bsky.social @vcumassey.bsky.social www.mdpi.com/2072-6694/17...

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis Background and Significance: Systemic immunoglobulin light chain (AL) amyloidosis remains a challenging disease, with current frontline regimens faili…

#teclistamab and #daratumumab as the first treatment for people with a new diagnosis of AL-amyloidosis. Details via #ASH25 (2/2) clinicaltrials.gov/study/NCT071...

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis Background and Significance: Systemic immunoglobulin light chain (AL) amyloidosis remains a challenging disease, with current frontline regimens faili…

A new clinical trial funded by @su2c.bsky.social and J&J for people with a difficult-to-treat disease called AL-amyloidosis. The trial, led by Dr. Suzanne Lentzsch of @columbiamed.bsky.social, will test the combination of (1/2) www.sciencedirect.com/science/arti...

Dr. Julian Adams, President and CEO of @su2c.bsky.social, is at the @milkeninstitute.org today discussing innovations in #EarlyDetection and equitable cancer care. Panelists include @boehmjesse.bsky.social from @break-cancer.bsky.social, Ian Foulkes from @cancerresearchuk.org, and Maddie Musselman

Last week, Dr. Julian Adams, President and CEO of @su2c.bsky.social, spoke at the #LongwoodHealthcareLeaders #BostonCEO 2025. The event covered a wide range of topics, including health equity and patient access to care. It was attended by top leaders in healthcare and select Nobel Laureates.

Will Freed-Pastor from @danafarber.bsky.social gave a phenomenal presentation on cryptic #antigens and their potential as targets for TCR-based therapies at the @theaacr.bsky.social Special Conference in #PancreaticCancer Research.

The 18th @theaacr.bsky.social Conference on the Science of #HealthDisparities took place in Baltimore from September 18-21. A special session held on Saturday featured a panel discussion, grantees, advocates, and other members of the @su2c.bsky.social community. Thanks to all in attendance!

Michael Goggins, Maria Irene Canto, and a team of @su2c.bsky.social and @lustgarten.org funded researchers at @hopkinsmedicine.bsky.social have found a link between dilation of the #pancreatic duct and the development of #pancreaticcancer in high-risk individuals. www.ghadvances.org/article/S277...

The Data for Children's and Young People's Cancer Programme Award is a new partnership between @su2c.bsky.social and @cancerresearchuk.org to support data-driven solutions to common challenges in this space.
More information: cruk.ink/4njVxWU
Informational webinar: cruk.ink/4gdAcw9